Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03SQT
|
|||
| Drug Name |
Q203
|
|||
| Synonyms |
Telacebec; 1334719-95-7; UNII-55G92WGH3X; 55G92WGH3X; Q-203; CHEMBL3298910; SCHEMBL12295312; MMV687696; BDBM50022086; ZINC169325657; CS-6412; Imidazo(1,2-a)pyridine-3-carboxamide, 6-chloro-2-ethyl-N-((4-(4-(4-(trifluoromethoxy)phenyl)-1-piperidinyl)phenyl)methyl)-; AS-35270; HY-101040; Q 203; EN300-218150; Z2235679010; 6-chloro-2-ethyl-N-[(4-{4-[4-(trifluoromethoxy)phenyl]piperidin-1-yl}phenyl)methyl]imidazo[1,2-a]pyridine-3-carboxamide; 6-chloro-2-ethyl-N-[[4-[4-[4-(trifluoromethoxy)phenyl]-1-piperidyl]phenyl]methyl]im
Click to Show/Hide
|
|||
| Indication | Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] | Phase 2 | [1] | |
| Tuberculosis [ICD-11: 1B10-1B1Z; ICD-10: A15-A19, B90] | Phase 1 | [2] | ||
| Company |
Qurient, Gyeonggi-do, South Korea
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C29H28ClF3N4O2
|
|||
| Canonical SMILES |
CCC1=C(N2C=C(C=CC2=N1)Cl)C(=O)NCC3=CC=C(C=C3)N4CCC(CC4)C5=CC=C(C=C5)OC(F)(F)F
|
|||
| InChI |
1S/C29H28ClF3N4O2/c1-2-25-27(37-18-22(30)7-12-26(37)35-25)28(38)34-17-19-3-8-23(9-4-19)36-15-13-21(14-16-36)20-5-10-24(11-6-20)39-29(31,32)33/h3-12,18,21H,2,13-17H2,1H3,(H,34,38)
|
|||
| InChIKey |
OJICYBSWSZGRFB-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1334719-95-7
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04847583) A Phase 2 Study to Evaluate Biomarker Change, Efficacy, Pharmacokinetics, Safety and Tolerability of Telacebec (Q203) in Covid-19 Patients. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.